The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | An analysis of the risk factors associated with disease progression in patients with BL
In this video, Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, discusses a multi-center retrospective analysis that aimed to evaluate prognostic risk factors associated with disease progression in adults with Burkitt lymphoma (BL). First, Dr Roschewski explains some background information from a previous clinical trial that investigated the use of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab (DA-EPOCH-R) in the treatment of lower-risk and higher-risk BL (NCT01092182). Following this, Dr Roschewski reports on the Burkitt lymphoma international prognostic index (BL-IPI), which is used to analyze risk factors in patients with BL. Dr Roschewski then goes on to explain the results from the retrospective analysis, focusing on features other than age that are highly prognostic in BL, including central nervous system (CNS) disease, bone marrow (BM) disease, and peripheral blood (PB) disease. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
